UROLOGIX INC Gross Margin
- Gross margin · 12 months: Value 47.74%; Formula and calculation Gross profit / revenue. Period ending 2015-03-31..
Gross margin
Overview →Financial period ending 2015-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 47.74% | Gross profit / revenue. Period ending 2015-03-31. $5.82M ÷ $12.19M × 100 ≈ 47.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 5.82M USD | Gross Profit |
| Revenue | 12.19M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2015-03-31 | $5.82M | $12.19M | (m) | 47.74% |
| 2014-12-31 | $5.36M | $12.75M | (m) | 42.02% |
| 2014-09-30 | $5.69M | $13.48M | (m) | 42.23% |
| 2014-06-30 | $6.09M | $14.23M | (m) | 42.80% |
| 2014-03-31 | $6.42M | $15.13M | (m) | 42.41% |
| 2013-12-31 | $7.59M | $15.85M | (m) | 47.90% |
| 2013-09-30 | $8.03M | $16.40M | (m) | 48.97% |
| 2013-06-30 | $8.18M | $16.59M | (m) | 49.32% |
| 2013-03-31 | $8.55M | $16.90M | (m) | 50.62% |
| 2012-12-31 | $8.93M | $17.56M | (m) | 50.87% |
| 2012-09-30 | $8.98M | $17.86M | (m) | 50.31% |
| 2012-06-30 | $8.38M | $17.03M | (m) | 49.23% |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | $6.54M | $12.57M | (m) | 52.03% |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | $8.20M | $14.77M | (m) | 55.53% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.